IL2 and type 1 diabetes mellitus: This trial will provide the opportunity to determine the minimum dose of IL-2 that could be used to initiate treatment of patients with newly diagnosed T1D, and, in the future, to test the possibility that ULD IL-2 can prevent the onset of autoimmunity, which occurs many years before disease diagnosis.